Research

    Clinical Trials Frequently Asked Questions

    The ALS Society of Canada’s (ALS Canada) vision is a future without ALS. To achieve this vision, new treatments that can help with symptom management and slow down and someday stop the progression of amyotrophic lateral sclerosis (ALS) need to undergo clinical trials on humans to ensure that they are both safe and effective before being approved for widespread availability.
    Research

    ALS Canada Gene Hub

    The ALS Society of Canada (ALS Canada) is committed to a future where anyone living with ALS, or with a known genetic risk of ALS, understands how genetics may impact them. We aim to provide accurate and relevant information, as well as pathways to action for those who wish to access genetic care.
    Research

    ALS And Genetics

    In familial ALS, an inherited genetic mutation causes ALS. Many different genetic mutations have been linked to ALS, and not all families have the same mutation as the cause of their disease.
    Research

    Annual Report 2023: Improving quality of life

    ALS Canada’s work is empowered by community. Discover how, in 2023, our collaboration with clinicians and investments in research aims to enhance care and the potential for future treatments.
    Research

    Guide to Reading Research Papers

    From unravelling abstracts to diving deep into discussions, this resource will help you feel more confident the next time you dig into a complicated ALS research paper.
    Events

    2024 ALS Canada Research Forum

    Bringing together researchers and community members to move the needle on ALS treatment and innovation
    Research

    ALS Canada Research Glossary

    This glossary contains a list of scientific and medical terms and definitions that are relevant to amyotrophic lateral sclerosis (ALS).
    Research

    Canadians living with ALS unite to CAPTURE ALS

    Amyotrophic lateral sclerosis (ALS) is a complex disease with varying symptoms and severity for people affected. Due to its heterogeneity, diagnosing the disease can be challenging and finding effective treatments can also be difficult.
    Research

    ALS Canada and Brain Canada invest more than half a million dollars in the future of ALS researchers with the 2023 Clinical Research Fellowship and Trainee Awards

    Toronto — In recognition of World Science Day, together with Brain Canada, the ALS Society of Canada (ALS Canada) is pleased to announce the 2023 ALS Canada-Brain Canada Clinical Research Fellowship and Trainee Award recipients. These early career grants are designed to support the training and research of clinicians in clinical care and PhD students and postdoctoral fellows engaged in research related to amyotrophic lateral sclerosis (ALS) across Canada.
    Research

    Can we reprogram cells we already have to replace neurons damaged by ALS? This postdoctoral fellow wants to find out

    Dr. Hussein Ghazale is the recipient of a $165,000 ALS Canada – Brain Canada 2022 Trainee Award. After finishing his PhD in France, Dr. Ghazale moved to Canada to work with Dr. Carol Schuurmans at Sunnybrook Research Institute. Her team examines if neuronal reprogramming could serve as a potential treatment strategy for neurodegenerative diseases, including ALS.
    Research

    PhD student Lucia Jadon opens new pathways for ALS research

    PhD student Lucia Meng Qi Jadon (previously Liao) is the recipient of a $75,000 ALS Canada – Brain Canada 2022 Trainee Award. She will use the funding to investigate whether a newly discovered tag on TDP-43 might have an important role to play in ALS.
    Research

    Charlotte Manser is turning her grief into hope for other families facing ALS

    Charlotte Manser is the recipient of a $75,000 ALS Canada – Brain Canada 2022 Trainee Award. As a PhD student at the University of Ottawa, she investigates how ALS-linked genes might contribute to the loss of normal stress granule formation.
    Research

    ALS Canada Research Update, October 2023

    ALS researchers from around the world continue to build upon existing work and make new discoveries in the hopes of realizing a future without ALS. In the October 2023 Research Update, you’ll learn about advances in understanding the presymptomatic stage of ALS, new guidelines for genetic testing and counselling, an experimental cell replacement strategy, new insights into cellular pathways disrupted in ALS, and more.
    Research

    Award fills funding gap for international student exploring understudied causes of ALS

    Donovan McDonald is the recipient of a $75,000 ALS Canada – Brain Canada 2022 Trainee Award. As a PhD student, he investigates how the function of tRNA could contribute to ALS disease processes.
    Research

    Funding allows a future change-maker in ALS to pursue innovative research

    Dr. Philip McGoldrick, a researcher at the Tanz Centre for Research in Neurodegenerative Diseases at the University of Toronto, is the 2022 recipient of a $250,000 ALS Canada – Brain Canada Career Transition Award.
    Research

    Dr. Alex Parker: Not giving up on the “hard problem” of ALS

    Dr. Alex Parker, at the Centre de recherche du CHUM, Université de Montreal, is one of the first two recipients of the newly introduced three-year, $300,000 ALS Canada-Brain Canada Discovery Grant. Dr. Parker’s grant was funded in generous partnership with Dr. Jean-Pierre Canuel Fund – SLA Québec.
    Research

    Dr. Gary Shaw: Exploring how cells “take out the trash” to find new therapeutic targets in ALS

    Dr. Gary Shaw is a biochemist at Western University and one of the nine ALS Canada-Brain Canada Discovery Grant recipients for 2022.